Aileron Therapeutics reports Q3 results
- Aileron Therapeutics press release (RNTX): Q3 Diluted loss per share of $0.06 vs. $0.21 Y/Y.
- Cash, cash equivalents and marketable securities totaled $36.5M as of September 30, 2026, expected to fund operations into Q1 2028 through completion of the Phase 2 RENEW trial of LTI-03.
R&D expenses of $4.4M, up 160% Y/Y.
G&A expenses of $2.6M, down 31% Y/Y.
Net loss of $5.5M vs. $5.6M Y/Y, down 1%.
Recommended For You
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
Black Friday: Create a Free Seeking Alpha Account
See what's moving the market with unlimited news access, and get 20% off your first year of any Seeking Alpha service.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.